Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles

被引:38
作者
Sivakumar, Padmanaban [1 ,4 ]
Kim, Sumin [2 ,3 ]
Kang, Han Chang [2 ,3 ]
Shim, Min Suk [1 ]
机构
[1] Incheon Natl Univ, Div Bioengn, Incheon 22012, South Korea
[2] Catholic Univ Korea, Coll Pharm, Integrated Res Inst Pharmaceut Sci, Dept Pharm, Bucheon, Gyeonggi Do, South Korea
[3] Catholic Univ Korea, Coll Pharm, PLUS Team Creat Leader Program Pharmac Based Futu, Bucheon, Gyeonggi Do, South Korea
[4] Indian Oil Corp Ltd, Qual Control Dept, Paradip Refinery, Kujang 754141, Odisha, India
基金
新加坡国家研究基金会;
关键词
aptamer; aptamer-siRNA chimera; nanocarriers; RNA interference (RNAi); siRNA; IN-VITRO SELECTION; RNA-INTERFERENCE; LIPID NANOPARTICLES; VIVO DELIVERY; CANCER-CELLS; TUMOR-GROWTH; GENE; INHIBITION; SYSTEM; BARRIERS;
D O I
10.1002/wnan.1543
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The sequence-specific gene-silencing ability of small interfering RNA (siRNA) has been exploited as a new therapeutic approach for the treatment of a variety of diseases. However, efficient and safe delivery of siRNA into target cells is still a challenge in the clinical development of siRNA-based therapeutics. Recently, nucleic acid-based aptamers that target cell surface proteins have emerged as a new class of targeting moieties due to their high specificity and avidity. To date, various aptamer-mediated siRNA delivery systems have been developed to enhance the RNA interference (RNAi) efficacy of siRNA via targeted delivery. In this review, we summarize recent advances in developing aptamer-mediated siRNA delivery systems for RNAi therapeutics, mainly aptamer-siRNA chimeras and aptamer-functionalized nanocarriers incorporating siRNA, with a focus on their molecular designs and formulations. In addition, the challenges and engineering strategies of aptamer-mediated siRNA delivery systems for clinical translation are discussed. This article is categorized under: Biology-Inspired Nanomaterials > Nucleic Acid-Based Structures Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
引用
收藏
页数:20
相关论文
共 108 条
[1]   Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model [J].
Alshaer, Walhan ;
Hillaireau, Herve ;
Vergnaud, Juliette ;
Mura, Simona ;
Delomenie, Claudine ;
Sauvage, Felix ;
Ismail, Said ;
Fattal, Elias .
JOURNAL OF CONTROLLED RELEASE, 2018, 271 :98-106
[2]  
[Anonymous], 2012, Drug Discov Today Technol, V9, pe71, DOI 10.1016/j.ddtec.2012.01.003
[3]   siRNA-Aptamer Chimeras on Nanoparticles: Preserving Targeting Functionality for Effective Gene Silencing [J].
Bagalkot, Vaishali ;
Gao, Xiaohu .
ACS NANO, 2011, 5 (10) :8131-8139
[4]   Chemical Modification of siRNAs for In Vivo Use [J].
Behlke, Mark A. .
OLIGONUCLEOTIDES, 2008, 18 (04) :305-319
[5]  
BEIGELMAN L, 1995, NUCLEIC ACIDS RES, V23, P4434
[6]   Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity [J].
Berezhnoy, Alexey ;
Castro, Iris ;
Levay, Agata ;
Malek, Thomas R. ;
Gilboa, Eli .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (01) :188-197
[7]   Thermal Stability of siRNA Modulates Aptamer-conjugated siRNA Inhibition [J].
Berezhnoy, Alexey ;
Brenneman, Randall ;
Bajgelman, Marcio ;
Seales, Dawn ;
Gilboa, Eli .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2012, 1 :e51
[8]   RNAi medicine for the brain: progresses and challenges [J].
Boudreau, Ryan L. ;
Rodriguez-Lebron, Edgardo ;
Davidson, Beverly L. .
HUMAN MOLECULAR GENETICS, 2011, 20 :R21-R27
[9]   The promises and pitfalls of RNA-interference-based therapeutics [J].
Castanotto, Daniela ;
Rossi, John J. .
NATURE, 2009, 457 (7228) :426-433
[10]   Targeting cancer cells with nucleic acid aptamers [J].
Cerchia, Laura ;
de Franciscis, Vittorio .
TRENDS IN BIOTECHNOLOGY, 2010, 28 (10) :517-525